Conclusions: Functional activation of Gα q proteins coupled to dopamine D 1 -like receptor and α 1 -adrenoceptor is detectable by means of [ 35 S]GTPγS binding/immunoprecipitation assay in rat brain membranes. Several compounds exhibit curious behaviors in this assay system, for which further investigations are necessary.
Abstract
Prenatal maternal infection represents a risk factor for schizophrenia and related disorders. In rodents, prenatal immune challenge with the viral mimetic poly(I:C) (polyriboinosinic-polyribocytidilic-acid) induces long-term behavioral deficits, highly relevant for schizophrenia and neurodevelopmental disorders. We have previously shown that the behavioral abnormalities in mice treated with poly(I:C) during late gestation are associated with significant impairments in the GABAergic transcriptome (1), one of the most robust change found in schizophrenia. Here we investigated the modulation of GABAergic markers in dorsal and ventral hippocampus of poly(I:C) treated mice, and we evaluated the effect of chronic lurasidone treatment (2) during adulthood on such parameters. Pregnant C57BL/6 mice were treated with poly(I:C) (5 mg/kg) or saline on gestation day 17. At adulthood, a cohort of mice was treated for 30 days with lurasidone at the dose of 1mg/kg/day by oral gavage. Animals were sacrificed 24h after the last drug administration and the brain regions were dissected and frozen on dry ice for the molecular analyses.
We found that prenatal immune challenge was able to reduce parvalbumin protein levels in the dorsal hippocampus, an effect that was normalized by lurasidone administration. Moreover, the levels of neuroligin-2 (NLGN-2), a synaptic cell adhesion molecule involved in the stabilization and maturation of GABAergic synapses, was decreased in the dorsal hippocampus of poly(I:C) mice and that these changes were also ameliorated by lurasidone administration.
Our findings demonstrate that poly(I:C)-induced immune challenge late in gestation produces enduring changes in GABAergic markers, primarily affecting the dorsal hippocampus. These changes may sustain behavioral defects produced by the prenatal infection, which are associated with an abnormal function of PV neurons. Interestingly, chronic treatment with lurasidone was able to counteract some of these changes in line with its potential to ameliorate cognitive functions that are deteriorated in psychiatric patients (2, 3).
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Upregulation of zinc transporter, solute carrier family 39, member 12, in the cortex of subjects with schizophrenia 
Abstract
Zinc is an important trace element essential for normal brain functioning, and thus requires tight regulation. Using an expression microarray we showed that mRNA for a zinc transporter, solute carrier family 39, member 12 (SLC39A12), was higher in the dorsolateral pre-frontal cortex of subjects with schizophrenia compared to control 1 . The aims of this study were to validate this finding using quantitative PCR (qPCR), measure the extent of this upregulation across the cortex, determine if changes show disease specificity or could be due to a mechanism of action of antipsychotic drugs, and confirm that this previously uncharacterised protein could transport zinc across the cell membrane.
qPCR was used to measure mRNA levels for the two known human SLC39A12 variants, 1 and 2, in Brodmann's areas (BA) 8, 9 and 44 from 30 subjects with schizophrenia and 30 age/sex matched control, as well as in BA 9 from 10 subjects with bipolar disorder (BPD), 10 with major depressive disorder (MDD) and 9 matched control. Slc39a12 mRNA was also measured in the cortex of rats treated with haloperidol, chlorpromazine or thioridazine for 12 months. 65 Zinc uptake was measured in Chinese hamster ovary (CHO) cells overexpressing SLC39A12 variant 1 or 2.
Levels of SLC39A12 variant 1 mRNA was higher in BA 8 and 44 from subjects with schizophrenia compared to control, while variant 2 was higher in schizophrenia in all cortical regions examined. There were no differences in levels of SLC39A12 mRNA in BA 9 from subjects with BPD or MDD, or in the rat cortex after treatment with antipsychotic drugs. 65 Zinc uptake was increased in cells overexpressing either SLC39A12 variant 1 or 2.
These findings suggest an upregulation of SLC39A12 in the cortex of people with schizophrenia, with a possible disruption in cortical zinc homeostasis contributing to the pathophysiology of the disorder.
